Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04180670
Other study ID # Sanko
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date December 1, 2019
Est. completion date September 2023

Study information

Verified date May 2023
Source Sanko University
Contact meltem uzun, Ph.D(c)
Phone 05346390534
Email meuzun@sanko.edu.tr
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Urinary incontinence (UI) is defined as involuntary urinary incontinence. In women with COPD, chronic coughing can often lead to UI. In this patient group, incontinence may be related to functional impairment, concomitant diseases and medications used. The aim of this study was to determine the incidence of urinary incontinence in patients with chronic obstructive pulmonary disease (COPD) and the factors that may be associated with urinary incontinence. The study included individuals who applied to the Pulmonary Diseases Policlinic of SANKO University Sani Konukoğlu Practice and Research Hospital and followed up with the diagnosis of COPD. The age, sex, height, weight, education level, smoking, exercise habits, fluid intake, medications and accompanying diseases such as heart disease, hypertension and diabetes will be recorded. Any prolapse or surgery will be questioned and noted. The disease severity will be determined by the forced expiratory volume (FEV1) value of the first second obtained from pulmonary function tests. Dyspnea score will also be determined by the Modified British Research Council (MBRC). Symptoms will be evaluated with the COPD Assessment Test (CAT). For urinary incontinence, the ICIQ-SF (International Urinary Incontinence Consultation) Questionnaire and Urinary Distress Inventory will be applied. In addition, the Leicester Cough Questionnaire will be used to assess your coughing functions, and the Activity-Self Assessment will be performed to determine the individual activity adequacy and the value of activities for individuals. All evaluations will be done only once with the help of the physiotherapist and asking the questions and recording the answers of the individual.


Description:

rinary incontinence (UI) is defined as involuntary urinary incontinence. In women with COPD, chronic coughing can often lead to UI. In this patient group, incontinence may be related to functional impairment, concomitant diseases and medications used. The aim of this study was to determine the incidence of urinary incontinence in patients with chronic obstructive pulmonary disease (COPD) and the factors that may be associated with urinary incontinence. The study included individuals who applied to the Pulmonary Diseases Policlinic of SANKO University Sani Konukoğlu Practice and Research Hospital and followed up with the diagnosis of COPD. The age, sex, height, weight, education level, smoking, exercise habits, fluid intake, medications and accompanying diseases such as heart disease, hypertension and diabetes will be recorded. Any prolapse or surgery will be questioned and noted. The disease severity will be determined by the forced expiratory volume (FEV1) value of the first second obtained from pulmonary function tests. Dyspnea score will also be determined by the Modified British Research Council (MBRC). Symptoms will be evaluated with the COPD Assessment Test (CAT). For urinary incontinence, the ICIQ-SF (International Urinary Incontinence Consultation) Questionnaire and Urinary Distress Inventory will be applied. In addition, the Leicester Cough Questionnaire will be used to assess your coughing functions, and the Activity-Self Assessment will be performed to determine the individual activity adequacy and the value of activities for individuals. All evaluations will be done only once with the help of the physiotherapist and asking the questions and recording the answers of the individual.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date September 2023
Est. primary completion date August 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Patients diagnosed with COPD Exclusion Criteria: - 65 and above patients Patients with congenital anomalies that may cause incontinence Patients with neurological diagnosis that may cause incontinence - Obese patients with BMI over 30 - Female patients with traumatic gynecological history - Patients with incontinence after severe gynecological operation

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Turkey SANKO University Gaziantep Please Select

Sponsors (1)

Lead Sponsor Collaborator
Sanko University

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary MMRC Dyspnea score Grade shortness of breath that may occur during daily exercises. "0" means shortness of breath with heavy exercise and 5 means shortness of breath even when dressing and undressing. First day
Primary COPD Assessment Test CAT It is an eight-item short, easy-to-apply test that measures the effects of COPD and deterioration in health status. The change in two units or more at the individual patient level is clinically significant. First day
Primary ICIQ-SF (International Urinary Incontinence Consultation) Survey It consists of 6 questions. In the first two questions, the date of birth and gender are questioned, while in the third question the incidence of urinary incontinence is questioned in the fourth question. 5. Question "How much incontinence affects your daily life?" Is answered between 0 (does not affect it in any way) and 10 (very much affects) and makes you think that the quality of life gets worse as you get closer to 10. In question 6, the time of incontinence is questioned. The maximum value is 21. The higher the score, the lower the quality of life. First day
Primary Urinary Distress Inventory It consists of 6 questions and is graded as a four-point Likert. The first two questions address irritative symptoms (urgency, frequency, and pain), while questions 3 and 4 aim at stress symptoms, and the last two questions address obstructive or voiding symptoms. First day
Primary Leicester Cough Survey It consists of 19 items, three of which are physical, psychological and social. The items in the Leicester Cough Questionnaire were selected by clinical effect factor method. This method selects the subjects that the patients define as problems and differentiates them according to the importance of the patients. Topics are also divided into fields. The questionnaire is completed on a seven-point Likert Scale (1 = Always, 2 = Most of the time, 3 = Often, 4 = Sometimes, 5 = Occasionally, 6 = Rarely, 7 = Never). Higher scores indicate better health status. Total score; It is the sum of the scores of the three subheadings (physical, psychological and social). First day
Primary Activity-Self Assessment It is an individual-centered assessment tool consisting of 21 questions related to the individual's kendisi self ali related to the activity activity (how well it performs the activity) and value (how valuable / important the relevant activity is for itself). The first 11 questions are skills; 12.-16. questions between habits and 17.-21. items related to requests. First day
See also
  Status Clinical Trial Phase
Completed NCT05102305 - A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
Completed NCT01867762 - An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease Phase 2
Recruiting NCT05562037 - Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA N/A
Terminated NCT04921332 - Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD N/A
Completed NCT03089515 - Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust N/A
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT05552833 - Pulmonary Adaptive Responses to HIIT in COPD N/A
Recruiting NCT05835492 - A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
Recruiting NCT05631132 - May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases? N/A
Completed NCT03244137 - Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
Not yet recruiting NCT03282526 - Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease N/A
Completed NCT02546700 - A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 2
Withdrawn NCT04446637 - Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD Phase 3
Completed NCT04535986 - A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD Phase 3
Recruiting NCT05865184 - Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
Completed NCT03295474 - Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
Completed NCT03256695 - Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 3
Withdrawn NCT04042168 - Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD) Phase 4
Completed NCT03414541 - Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease Phase 2
Completed NCT02552160 - DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy